Taken together, our model predicts that the best candidates for adding GLP-1 M as a second line T2D medication are: older age, non-Asian subjects, with short T2D duration that have elevated HbA1C, high BMI, hypertension, and no heart failure or retinopathy. This evidence concerns the gene GLP1R and heart failure.